1.Analysis of the Influence of Different Scanning Conditions of Medical Linear Accelerator CBCT on Image Quality.
Li LIU ; Chengwei YE ; Jianjun YUAN ; Yingui LUO ; Zhiyao LUO ; Wei ZENG ; Ling LI ; Huan LIU ; Yan LIU
Chinese Journal of Medical Instrumentation 2025;49(2):176-180
OBJECTIVE:
To investigate the influence of different scanning conditions on the image quality of medical electron accelerator cone-beam computed tomography (CBCT) and provide a reference for the selection of scanning conditions for different body parts. Methods Set different scanning conditions, the Catphan 503 phantom was scanned using CBCT parameters to analyze the influence of spatial resolution, noise, uniformity, spatial geometric accuracy, and low-contrast resolution on the image quality of CBCT.
RESULTS:
For the head, chest, and abdomen, with the increase in scanning parameter values, the noise value decreased by 47.4%, 26.1%, and 51.3% respectively, and the uniformity values decreased by 30.2%, 26.6%, and 47.9% respectively. The low-contrast resolution values decreased by 50.6%, 34.2%, and 12.0%. The influence of different scanning conditions on spatial geometric accuracy and spatial resolution is not significant.
CONCLUSION
Different scanning parameters have a certain influence on the image quality of medical electron accelerator CBCT. Lower scanning parameters can be selected based on individual patients to reduce the additional radiation dose, providing a reference for the safe application of CBCT image guidance in radiotherapy.
Cone-Beam Computed Tomography/instrumentation*
;
Phantoms, Imaging
;
Particle Accelerators
2.Research Advances in Tetraspanins in Colorectal Cancer
Chengwei LIU ; Kunyang WANG ; Zhen HU ; Yaoping LI
Cancer Research on Prevention and Treatment 2025;52(5):361-367
The tetraspanins are closely associated with the development and therapeutic prognosis of colorectal tumors. These proteins play a role in cell proliferation, metastasis, and invasion, regulate apoptosis and autophagy of colorectal tumor cells. affect immune escape by releasing exosomes, intervening the epithelial-mesenchymal transition process, and altering the tumor microenvironment, and enhance tumor stemness through specific pathways. This paper reviews the mechanisms and current research regarding the status of tetraspanins in colorectal cancer, aiming to improve early diagnosis and providing valuable insights for treatment strategies.
3.Research Progress of Clinical Quality Control Phantoms for MRI Equipment
Chengwei LI ; Jiao LI ; Hui XU ; Tianrui ZHAO ; Pu ZHANG ; Peng ZHANG ; Zhengshan HUANG ; Jie SUN
Chinese Journal of Medical Imaging 2025;33(6):607-610,617
With the rapid increase of MRI systems in hospitals in China,national multi-sectoral strategies have been put forward to clarify requirements for improving image quality of MRI systems and preventing application risks in clinic.Quality control of MRI systems becomes an important task for regulators as well as hospital radiology departments.The tools used for quality control include imaging performance phantom and specialized function phantom,which can realize detection or calibration for parameters such as high contrast resolution,image uniformity and relaxation time.This article mainly reviews the research progress of the operation principles,common types and clinical applications for these two types of phantoms mentioned above.
4.Analysis of the efficacy of lamb′s tripe extract and vitamin B 12 capsule on chronic atrophic gastritis at different sites
Dongdong XIA ; Huahong XIE ; Bo JIANG ; Hong XU ; Zhanguo NIE ; Chengwei TANG ; Qiang GUO ; Xiaoping ZOU ; Shuisheng SHI ; Tao SUN ; Shourong SHEN ; Guoqing LI ; Xiaozhong GUO ; Xiaoyan ZHAO ; Jiaming QIAN ; Weixing CHEN ; Guiying ZHANG ; Aijun LIAO ; Jingyuan FANG ; Daiming FAN ; Kaichun WU
Chinese Journal of Digestion 2025;45(3):162-168
Objective:To evaluate the efficacy of lamb′s tripe extract and vitamin B 12 capsule (LTEVB 12C) on chronic atrophic gastritis (CAG) at different locations (antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and corpus greater curvature). Methods:From August 2011 to January 2013, 715 patients with CAG in a multicenter, randomized, double-blind, placebo-controlled trial were enrolled from 16 tertiary first-class hospitals across the country, including the First Affiliated Hospital of Air Force Medical University, Nanfang Hospital of Southern Medical University, the First Hospital of Jilin University, West China Hospital of Sichuan University, etc., there were 476 cases in the LTEVB 12C group and 239 cases in the placebo group. The patients of the LTEVB 12C group received LTEVB 12C, and the patients of placebo group received LTEVB 12C mimetic, all the medications were taken 3 capsules each time and 3 times a day after meals, and the treatment course of 2 groups were both 6 months. The efficacy evaluation criteria included the effective rate (a decrease of ≥1 in histopathological score compared with baseline after 6 months of treatment) and the reversal rate (a decrease of ≥ 2 in histopathological score compared with baseline after 6 months of treatment in the patients with moderate to severe CAG). The impact of lesion sites on the therapeutic effects of LTEVB 12C was analyzed by logistic regression analysis. The two-way unordered Cochran-Mantel-Haenszel chi-square test considering the center effect and Pearson chi-square test were used for statistical analysis. Results:The effective rates of chronic inflammation at the antrum greater curvature and corpus greater curvature (23.3%, 110/473 vs. 13.0%, 31/239; 20.3%, 96/472 vs. 12.6%, 30/239), the effective rates of atrophy at the antrum lesser curvature, antrum greater curvature, gastric angle, corpus lesser curvature, and the corpus greater curvature (27.0%, 118/437 vs. 15.7%, 34/216; 29.2%, 126/432 vs. 18.5%, 38/205; 27.8%, 121/435 vs. 16.7%, 36/216; 32.5%, 127/391 vs. 19.8%, 37/187; 33.0%, 119/361 vs. 21.8%, 39/179), and the effective rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (45.0%, 112/249 vs. 29.8%, 31/104; 53.8%, 86/160 vs. 33.9%, 21/62; 45.8%, 103/225 vs. 24.0%, 25/104; 51.9%, 83/160 vs. 28.3%, 17/60) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=10.76, 6.39, 9.69, 7.91, 11.05, 9.62, 8.57, 5.20, 7.11, 12.45, and 6.73; all P<0.05). The reversal rates of chronic inflammation at the corpus lesser curvature and corpus greater curvature (5.2%, 12/231 vs. 0, 0/123; 4.7%, 8/170 vs. 0, 0/88), the reversal rates of atrophy at the antrum lesser curvature, antrum greater curvature, corpus lesser curvature, and the corpus greater curvature (6.8%, 22/323 vs. 1.3%, 2/151; 9.2%, 29/315 vs. 1.4%, 2/144; 14.2%, 38/267 vs. 2.5%, 3/121; 20.8%, 35/168 vs. 5.8%, 4/69), and the reversal rates of intestinal metaplasia at the antrum lesser curvature, antrum greater curvature, gastric angle, and the corpus lesser curvature (29.8%, 39/131 vs. 9.1%, 4/44; 41.0%, 32/78 vs. 12.5%, 3/24; 33.3%, 44/132 vs. 4.8%, 3/63; 50.0%, 37/74 vs. 8.7%, 2/23) of the LTEVB 12C group were all higher than those of the placebo group, and the differences were statistically significant ( χ2=6.58, 5.12, 5.60, 8.61, 11.43, 6.59, 7.30, 4.95, 15.92, 7.62; all P<0.05). There were no statistically significant differences in the effective rates and reversal rates of active inflammation at different locations between the LTEVB 12C group and the placebo group (all P>0.05). The results of logistic regression analysis (taking the antrum lesser curvature as the reference) further confirmed that the reversal rates of chronic inflammation ( OR=0.22, 95% confidence interval (95% CI): 0.07 to 0.67; OR=0.24, 95% CI: 0.07 to 0.80), atrophy ( OR=0.28, 95% CI: 0.16 to 0.49; OR=0.28, 95% CI: 0.16 to 0.49), and intestinal metaplasia ( OR=0.42, 95% CI: 0.24 to 0.77; OR=0.20, 95% CI: 0.08 to 0.52) at the corpus lesser curvature and corpus greater curvature were all higher than those at the antrum lesser curvature, and the differences were statistically significant (all P<0.05). There were no statistically siginificant differences in the reversal rates of the aforementioned pathological features between the antrum greater curvature, gastric angle, and the antrum lesser curvature (all P>0.05). Conclusion:LTEVB 12C can achieve good efficacy in the treatment of CAG, and the chronic inflammation, atrophy, and intestinal metaplasia at multiple locations are improved, especially at the corpus lesser curvature and the corpus greater curvature.
5.Strengthening the Construction of Clinical Quality Control System for MRI Equipment to Ensure Their Efficacy in Clinical Application
Hongxia YIN ; Chengwei LI ; Yawen LIU ; Hui XU ; Yu ZHANG ; Zhenchang WANG
Chinese Journal of Medical Imaging 2025;33(6):583-586
With the rapid increase in the ownership of MRI equipment in China,quality control,particularly in clinical usage aspects,has become critically important.For clinical quality control of MRI systems,it is essential to establish comprehensive workflow principles encompassing multiple elements such as personnel,equipment,standards,tools and methodologies.To advance the standardization and widespread adoption of clinical quality control for MRI equipment,efforts must focus on strengthening regulatory frameworks,advancing phantom research,development and enhancing professional expertise.Concurrently,continuous improvements in training programs and supervision mechanisms are necessary to ensure the effective implementation of MRI clinical quality control practices.Furthermore,in the era of digital healthcare,clinical quality assurance for MRI equipment is evolving toward automation and intelligent solutions,providing higher-quality and more efficient assurance for clinical applications.
6.Whole-Body Specific Absorption Rate Measurement Method Based on NIM Calorimetry
Zhengshan HUANG ; Pu ZHANG ; Peng ZHANG ; Chengwei LI ; Jie SUN
Chinese Journal of Medical Imaging 2025;33(6):589-594
Purpose To explore the feasibility and practical value of using National Institute of Metrology(NIM)calorimetry method to measure whole-body specific absorption rate(SAR)values of in-service MRI equipment.Materials and Methods A NIM calorimetry device for measuring whole-body SAR values was developed,SAR values of different MRI devices were measured by NIM calorimetry,and compared with National Electrical Manufacturers Association(NEMA)calorimetry and pulse-energy method to verify the measurement accuracy and applicability of the NIM calorimetry method.Results The NIM calorimetry device developed in this study had reliable performance,and the experimental results indicated the difference in measurement results between NIM calorimetry(1.63 W/kg)and NEMA calorimetry(1.80 W/kg)was within 10%.The difference between the SAR measurement results of multiple MRI devices based on NIM calorimetry(0.46,0.93,0.61 W/kg)and the pulse energy method(0.42,0.89,0.56 W/kg)was within 10%.Conclusion The NIM calorimetry method in this study can accurately measure whole-body SAR values and has applicability.
7.Maribavir effectively treated three patients with human herpesvirus-6B infection after allogeneic hematopoietic stem cell transplantation
Chengwei JIN ; Su LI ; Luxiang WANG ; Jiayu HUANG ; Xiaoxia HU ; Zilu ZHANG
Chinese Journal of Hematology 2025;46(7):663-665
Human herpesvirus-6B (HHV-6B) reactivation is a significant contributor to nonrelapse mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). This retrospective analysis describes three cases of HHV-6B reactivation following allo-HSCT, all of which achieved viral clearance with maribavir treatment following failure or intolerance to first-line antiviral therapy with foscarnet sodium. One patient diagnosed with HHV-6B encephalitis recovered without neurological sequelae. No adverse drug reactions to maribavir were observed. These findings provide preliminary evidence that maribavir may serve as an effective and safe salvage therapy for HHV-6B reactivation in patients receiving allo-HSCT.
8.Analysis of peripheral blood monocyte subsets in chronic myelomonocytic leukemia: a single-center study
Lin WANG ; Minming LI ; Jiaojiao BAI ; Chengxin DENG ; Ping WU ; Chengwei LUO ; Peilong LAI ; Jianyu WENG ; Xin DU
Chinese Journal of Hematology 2025;46(10):952-957
Objective:To evaluate the clinical value of peripheral blood monocyte subset analysis in the diagnosis and treatment of chronic myelomonocytic leukemia (CMML) .Method:We retrospectively enrolled 51 patients newly diagnosed with CMML at Guangdong Provincial People's Hospital between June 1, 2020, and December 31, 2024, according to the WHO 2022 diagnostic criteria. Twenty-three patients with other myeloid neoplasms (excluding CMML) and peripheral monocytosis (absolute count ≥0.5×10 9/L and percentage ≥10%) were included as the control group. All patients underwent bone marrow aspiration for examinations including bone marrow smears, biopsies, cytogenetics, and gene mutation analysis to establish a definitive diagnosis. Concurrently, flow cytometry was used to determine the proportions of peripheral blood monocyte subsets: classical (MO1, CD14 +CD16 -) , intermediate (MO2, CD14 +CD16 +) , and non-classical (MO3, CD14 lowCD16 +) . Differences between the groups were compared, and diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. Result:Among the 51 CMML patients, the proportion of the peripheral blood MO1 subset was significantly higher than that in patients with other myeloid neoplasms ( P=0.027) , whereas there were no significant differences in the MO2 and MO3 subsets (all P>0.05) . Further analysis revealed that 43 (84.31%) of the CMML patients met the WHO diagnostic threshold for the MO1 subset (≥94%) , while the remaining 8 patients did not; 46 patients (90.20%) had MO3 subset proportions below the threshold proposed by Hudson (≤1.13%) , while the remaining 5 patients were above this threshold. In-depth analysis showed that among the 8 patients who did not meet the WHO criteria, 7 were experiencing inflammation. Similarly, all 5 patients who did not meet the Hudson criteria were in an inflammatory state. Subsequent ROC curve analysis of this cohort identified a cut-off value for the MO1 subset of 97.55% [Area Under the Curve (AUC) =0.661, P=0.027], which aligns with the WHO criteria. Conclusion:Peripheral blood monocyte subset analysis, particularly MO1 subset analysis, can effectively assist in CMML diagnosis, but exclusion of inflammatory conditions is required.
9.Discovery of fernane-type triterpenoids from Diaporthe discoidispora using genome mining and HSQC-based SMART technology.
Yajing WANG ; Yongfu LI ; Yan DONG ; Chunyan YU ; Chengwei LIU ; Chang LI ; Yi SUN ; Yuehu PEI
Chinese Journal of Natural Medicines (English Ed.) 2025;23(3):368-376
In this study, we employed a combination of genome mining and heteronuclear single quantum coherence (HSQC)-based small molecule accurate recognition technology (SMART) technology to search for fernane-type triterpenoids. Initially, potential endophytic fungi were identified through genome mining. Subsequently, fine fractions containing various fernane-type triterpenoids were selected using HSQC data collection and SMART prediction. These triterpenoids were then obtained through targeted isolation and identification. Finally, their antifungal activity was evaluated. As a result, three fernane-type triterpenoids, including two novel compounds, along with two new sesquiterpenes and four known compounds were isolated from one potential strain, Diaporthe discoidispora. Their structures were elucidated through analysis of high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) and nuclear magnetic resonance (NMR) spectroscopic data. The absolute configurations were determined using single-crystal X-ray diffraction analysis and electron capture detector (ECD) analysis. Compound 3 exhibited moderate antifungal activity against Candida albicans CMCC 98001 and Aspergillus niger.
Triterpenes/isolation & purification*
;
Antifungal Agents/isolation & purification*
;
Molecular Structure
;
Candida albicans/drug effects*
;
Ascomycota/genetics*
;
Magnetic Resonance Spectroscopy
;
Aspergillus niger/drug effects*
;
Genome, Fungal
;
Microbial Sensitivity Tests
10.Treatment of trigeminal neuralgia with botulinum toxin type A and cobrotoxin: a case report
Yingying XU ; Shuyang MA ; Ying LI ; Jili BAO ; Zhou XU ; Chengwei GUO ; Jing LIU ; Weifeng LUO
Chinese Journal of Neurology 2025;58(4):426-429
Trigeminal neuralgia is characterized by intense pain in the sensory distribution area of the trigeminal nerve. It can be triggered by non-noxious stimuli such as brushing teeth and washing face. At present, the treatment of trigeminal neuralgia mainly includes oral drugs and surgical treatments. A 92-year-old patient with trigeminal neuralgia was reported. The pain could not be alleviated because the patient was unable to tolerate the side effects of drugs and surgical treatment. Taking into account the onset time and the duration of the curative effect, botulinum toxin type A was combined with cobrotoxin for the treatment of the patient. As a result, the pain symptoms were rapidly alleviated and remained in a relieved state for 8 months. The clinical characteristics of this patient were summarized in this article, and the possible synergistic mechanisms of action of the 2 drugs were discussed. The ultimate objective is to furnish a broader spectrum of alternatives and references for clinical practice.

Result Analysis
Print
Save
E-mail